Results 131 to 140 of about 9,741 (153)

Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial

Lancet, The, 2020
Hyo-Soo Kim, Jeehoon Kang, Doyeon Hwang
exaly  

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

Lancet, The, 2009
C Michael Gibson
exaly  

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction

Circulation, 2020
Giuseppe Gargiulo, Giovanni Esposito, Michael Nagler   +2 more
exaly  

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

Lancet, The, 2009
Michelle L O'donoghue, Eugene Braunwald, Elliott M Antman   +2 more
exaly  

Prasugrel

Reactions Weekly, 2019
openaire   +1 more source

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

New England Journal of Medicine, 2019
Stefanie Schulz, Franz-Josef Neumann, Katharina Mayer   +2 more
exaly  

Prasugrel

Reactions Weekly, 2016
openaire   +1 more source

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

New England Journal of Medicine, 2007
Eugene Braunwald, Stefano De Servi, C Michael Gibson   +2 more
exaly  

Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Circulation, 2020
Gjin Ndrepepa, Franz-Josef Neumann, Katharina Mayer   +2 more
exaly  

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

Lancet, The, 2010
Marc S Sabatine
exaly